Puli's new product has been launched in both China and the United States, and the classic drug for a

Both China and the United States have reported that the classic anti infective drug, Puli Pharmaceutical, has been approved for market by the National Medical Products Administration for injection of doxycycline hydrochloride! Hainan Puli Pharmaceutical Co., Ltd. (hereinafter referred to as "Puli Pharmaceutical" or "the Company") recently received a drug registration approval from the National Medical Products Administration for injectable doxycycline hydrochloride (specifications: zero.one, zero.twog), which is considered to have been approved for market through consistency evaluation and will have a positive impact on expanding the domestic market. Puli Pharmaceutical has two approved specifications for the injection of doxycycline hydrochloride in China: zero.one and zero.two grams. The company's injectable doxycycline hydrochloride is a product that has been reported in both China and the United States, with guaranteed quality and safety. It will provide high-quality medication options for domestic patients. Invitation for cooperation, domestic investment promotion: one. Drug introduction Doxycycline is a classic tetracycline antibiotic with a wide range of antibacterial effects, which can effectively inhibit the growth of atypical pathogenic bacteria, Gram positive and Gram negative bacteria. Clinically, it is mainly used to treat various diseases such as rickettsia, mycoplasma infections, chlamydia infections, including mycoplasma pneumonia (respiratory/pediatric), pelvic inflammatory diseases (gynecological), non gonococcal urethritis (urology), etc. The sales growth is considerable, but the market competition is small. According to data from MiNet, in recent years, the sales growth of Doxycycline injection in the market is considerable. From two thousand twenty-two to Hone (Hone: the first half of the year), the sales revenue were fifty-eight million yuan, one hundred and twenty-eight million yuan, and ninety-two million yuan respectively, with an average annual growth rate of seventy-three%. In terms of sales volume, the Hone period from two thousand twenty-two to two thousand twenty-four (Hone: first half of the year) was one.forty-four million units, three.sixty-nine million units, and two.seventy-nine million units respectively, with an average annual growth rate of ninety-seven%. two thousand twenty-fourHone: In addition, in the first half of two thousand twenty-four, Puli Pharmaceutical's injectable doxycycline hydrochloride was the third of its kind to pass the consistency evaluation (currently only three have been evaluated), and there have been no other manufacturers to apply for consistency evaluation of this variety in the future. According to the tenth batch of national centralized procurement situation, usually there are seven manufacturers that have passed the evaluation before they can be included in centralized procurement. Currently, injectable doxycycline hydrochloride is far from meeting the conditions for centralized procurement and there are no other companies applying for it. This variety has relatively low competitive pressure and is expected to bring strong momentum to the company's performance growth in the future. three Sino US Dual Reports, High Quality Assurance: Puli Pharmaceutical's injectable doxycycline hydrochloride is a Sino US dual report product. The domestic and American markets share the same production line, with the same quality standards and product quality, providing high-quality medication choices for domestic patients. According to IMS data, the global sales of doxycycline injections have been around five hundred million yuan in recent years, indicating a stable overall market. Among them, the US market accounts for sixty-six.eight% of the global market share (Puli has been approved and has achieved drug exports), and the Chinese market is the third largest market in the world (eleven.two%). Sincere invitation for cooperation, domestic investment promotion: Regarding Puli Pharmaceutical, founded in Haikou in one thousand nine hundred and ninety-two, Puli Pharmaceutical is a leading enterprise in the internationalization of Chinese pharmaceutical preparations and a demonstration enterprise of intelligent manufacturing by the Ministry of Industry and Information Technology. It has been included in the key project enterprise of Made in China two thousand twenty-five for industrial transformation and upgrading by the Ministry of Industry and Information Technology. In two thousand twenty-three, Puli Pharmaceutical in Hainan passed the customs "AEO" advanced certification. Previously, Hainan Puli and its subsidiaries Zhejiang Puli and Anhui Puli have also successfully passed on-site audits by the US FDA and EU EMA multiple times. As a leading enterprise in the internationalization of Chinese pharmaceutical preparations, Puli Pharmaceutical has been adhering to high global quality standards for many years. It is one of the few domestic platforms for the research and production of active pharmaceutical ingredients and injections, and also one of the few high-quality suppliers of active pharmaceutical ingredients, key excipients, pharmaceutical drugs, and GMP intermediates CMO/CDMO approved by drug regulatory authorities in the United States, China, and the European Union. (Puli Pharmaceutical)